What is the best app to track MOTS-c?

Regimen is the top-rated MOTS-c tracker app. It logs every dose, visualizes estimated medication levels, and correlates your protocol to energy, body composition, resting heart rate, and lab values synced from Apple Health or Google Health Connect. Free for one compound with every feature unlocked. Rated 4.9 stars on iOS and Android.

MOTS-c Guide 2026: What It Is, How People Use It, What to Track

MOTS-c is the mitochondrial-derived peptide that got most of its early press for "exercise in a vial" headlines and then mostly faded into the background while the GLP-1 wave took over. The people who kept running it are mostly the metabolic-optimization crowd: lifters in their 40s and 50s, biohackers tracking glucose with a CGM, and a smaller group of clinicians using it as a metabolic adjunct alongside TRT or GH-axis stacks. This guide walks through what MOTS-c actually is, what the human evidence supports (and doesn't), how the community uses it in practice, and what to track if you decide to run it.

The Bottom Line

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome that signals to skeletal muscle, the liver, and adipose tissue to improve glucose handling, fat oxidation, and metabolic flexibility. It is not FDA-approved. Human data is limited to a small number of clinical pharmacology studies; the bulk of the evidence is preclinical (mice and cell lines). Community protocols typically run 5 to 10 mg subcutaneously two to three times per week in 4 to 12 week cycles. The felt response, when present, is mostly energy, exercise capacity, and recovery between sessions. MOTS-c is on the FDA's Category 2 list and on the agenda for the July 2026 Pharmacy Compounding Advisory Committee review.

What MOTS-c actually is

MOTS-c (Mitochondrial Open Reading frame of the 12S rRNA-c) is a small peptide encoded inside the mitochondrial genome rather than the nuclear DNA where almost every other peptide hormone is encoded. It was identified in 2015 by Pinchas Cohen's group at USC, in the broader class of mitochondrial-derived peptides (MDPs) along with humanin and the SHLP family.

The reason it got attention: MOTS-c circulates in blood, levels decline with age, and exercise transiently increases circulating MOTS-c. In mouse models, exogenous MOTS-c improves insulin sensitivity, reduces diet-induced obesity, increases exercise capacity, and partially reverses age-related metabolic decline. That combination is what produced the "exercise mimetic" framing in popular press, which is overstated but not entirely wrong.

How it works (mechanism in plain English)

Three jobs to know.

AMPK activation. MOTS-c activates AMP-activated protein kinase (AMPK) in skeletal muscle, the same metabolic sensor that responds to exercise, fasting, and metformin. AMPK activation shifts cells toward fat oxidation, glucose uptake, and mitochondrial biogenesis. This is the central mechanism that ties most of the downstream effects together.

Glucose disposal. Via AMPK and related pathways, MOTS-c improves skeletal muscle glucose uptake independently of insulin in animal models. The practical translation, if it holds in humans, is better post-meal glucose handling and reduced reliance on insulin to clear a given carbohydrate load.

Mitochondrial signaling. MOTS-c also moves into the nucleus under metabolic stress and helps regulate the expression of nuclear genes involved in mitochondrial function. This is the part of the mechanism most directly tied to the "metabolic flexibility" and "exercise capacity" claims, and the part with the thinnest human data.

What the evidence actually says

The evidence base has three layers, and the gap between them is wide.

Preclinical (mouse and cell) data. The strongest layer. Mouse studies show MOTS-c administration improves insulin sensitivity, reduces fat mass on a high-fat diet, increases running endurance, and reverses some age-related metabolic markers. Cell line work supports the AMPK and glucose-uptake mechanisms. Real science, done in mice, and the picture is consistent.

Human physiology studies. Endogenous circulating MOTS-c levels have been measured in humans across age, fitness, and disease cohorts. The patterns track expectations: levels decline with age, are lower in type 2 diabetes, and rise transiently with exercise. This is correlation, not intervention.

Human intervention trials with exogenous MOTS-c. The thinnest layer. A small number of early-phase clinical pharmacology studies have looked at safety and basic pharmacokinetics of injected MOTS-c. Larger efficacy trials in humans (for insulin resistance, obesity, exercise capacity, or anything else) have not been published as of this writing. The "MOTS-c works in humans for X" claim is currently inference from mouse data plus mechanism, not direct evidence.

Honest read: the biology is interesting and plausible, the animal data is consistent, the human intervention data is mostly missing. Treat your own response as the most relevant data point you have.

A note on FDA status

MOTS-c is not FDA-approved for any indication. It sits on the FDA's Category 2 list (substances with significant safety risk or insufficient data concerns for compounding). The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet July 23 to 24, 2026 to review MOTS-c (alongside BPC-157, TB-500, KPV, DSIP, Semax, and Epitalon) for possible 503A bulk-list treatment. The outcome could shift legal sourcing pathways significantly.

How the community actually uses it

No FDA-approved protocol exists, so what follows is what the metabolic-optimization community has converged on. Descriptive, not prescriptive.

Dose and frequency. The most common pattern is 5 to 10 mg subcutaneously, two to three times per week. A smaller subset runs 1 to 2 mg daily, on the theory that more frequent low doses better mimic endogenous signaling. Both patterns show up in community reports. Most users start at the lower end (5 mg twice weekly) and titrate.

Cycle length. 4 to 12 weeks on, then off for an equivalent block. MOTS-c is not run year-round in any community protocol that has any sourcing behind it; the prevailing logic is that mitochondrial signaling pathways adapt with chronic exposure and the off-cycles preserve responsiveness.

Timing relative to training. Some users inject on training days (often pre-workout) on the rationale that MOTS-c amplifies the exercise signal it normally rides on. Others inject on a fixed weekly schedule independent of training. There's no human data to adjudicate this; the pre-workout pattern is more popular among lifters.

Injection route. Subcutaneous in the abdomen or thigh. Intramuscular near a specific muscle group is sometimes used by lifters trying to bias the systemic effect locally, though there's no evidence it changes outcomes.

Who uses it (and what they're trying to do)

Three patterns show up most often.

The metabolic optimizer. Adult, often in their 40s or 50s, tracking glucose with a CGM, running TRT or thinking about it, and looking for an adjunct that improves insulin sensitivity and metabolic flexibility without the appetite-suppression side effect profile of GLP-1s. The most common use case in current community protocols.

The lifter chasing recovery and capacity. Less interested in body composition specifically, more interested in whether they recover faster between hard sessions and whether work capacity stays high through a heavy block. Often stacks MOTS-c with CJC-1295 plus ipamorelin or TRT.

The longevity-curious user. Running MOTS-c because the mitochondrial biology overlaps with rapamycin, metformin, and senolytic conversations they're already part of. Tends to log subjective markers (energy, sleep, recovery) more than objective ones. The most variable group in terms of perceived response.

What unites all three: MOTS-c is a metabolic adjunct, not a primary intervention. Nobody running it expects it to do what a GLP-1 does for weight or what TRT does for testosterone. They're running it because the underlying biology fits a niche their primary stack doesn't cover.

Sourcing reality

MOTS-c is not available through standard pharmacies for general use. Some compounding pharmacies have served it under varying interpretations of FDA Category 2 status; the broader market runs through research peptide vendors that ship product labeled "for research use, not for human consumption."

Quality control is uneven. Public testing of gray-market peptides has consistently found purity variation, mislabeling, and content discrepancies. MOTS-c is a relatively complex peptide to synthesize correctly, and at gray-market prices the incentive structure for vendors to cut corners is real. HPLC certificates of analysis from the vendor are the floor, not the ceiling. The July 2026 PCAC meeting may further restrict legal pathways. This guide is not a sourcing recommendation.

Running MOTS-c? Track the markers that actually move.

Dose log with PK curve estimates
Energy, RHR, body composition, and glucose overlays
Cycle on/off scheduling with side-effect notes

Regimen peptide and GLP-1 tracker app screenshot

Side effects and risks

Human safety data is limited. Reported community side effects are mostly mild and transient: occasional fatigue or flu-like feeling in the first few doses, injection-site irritation, and occasional GI changes (mild loose stools, transient appetite changes). Most users report nothing notable after the first one to two weeks.

The theoretical concerns in the literature are about metabolic side effects: because MOTS-c lowers blood glucose, stacking it with other glucose-lowering agents (metformin, GLP-1s, insulin) could theoretically push glucose too low, especially in lean users with already-good insulin sensitivity. Reports of symptomatic hypoglycemia on MOTS-c alone are rare in healthy users but are worth knowing about if you're stacking. Drug interaction data is limited overall.

Who it's not for

Anyone with type 1 diabetes or insulin-treated type 2. The glucose-lowering effect plus exogenous insulin is a real hypoglycemia setup. Do not run without an endocrinologist's input.
Pregnant or breastfeeding women. No safety data.
Tested athletes. MOTS-c is not currently a named substance on the WADA prohibited list, but the "Peptide Hormones, Growth Factors, Related Substances and Mimetics" category (S2) is interpreted broadly. The safe assumption for anyone in tested sport is that any peptide outside an approved medication is at meaningful risk of being treated as prohibited. Don't run without explicit guidance from your sport's anti-doping authority.
Anyone with an active cancer history. The mitochondrial-signaling and metabolic effects are not well characterized in the context of malignancy. Caution and oncology input are warranted.

What to track on a MOTS-c protocol

The felt response is subtle, so a baseline matters more than usual. Practical markers:

Subjective energy (1-10 rating, morning and afternoon)
Exercise capacity (RPE on standard sessions; sessions completed at planned intensity)
Resting heart rate (wearable trend; MOTS-c users often report a modest drop)
Body composition (weight and body fat percentage, weekly)
Fasting glucose (daily if you have a CGM, weekly if you don't)
HbA1c and lipid panel (pre-cycle and post-cycle)
Sleep quality (wearable trend across the cycle)
Side effects (fatigue, GI, injection-site reactions, any hypoglycemic episodes)

Start logging at least two weeks before the protocol so you have a baseline. The most common reason people can't tell if MOTS-c worked is they didn't measure anything beforehand.

What we see in Regimen data

MOTS-c is a small but consistent compound in Regimen's metabolic-optimization cohort. Users tracking MOTS-c are more likely than the platform average to also be logging a CGM-derived glucose marker, resting heart rate, and TRT or a GH-axis peptide, which fits the metabolic-adjunct use case rather than a standalone protocol. The compound shows up most often in 6 to 10 week cycles with at least one off-cycle in between, consistent with the descriptive community pattern.

Stacks and combinations

MOTS-c shows up most often as an adjunct rather than a primary compound.

MOTS-c with TRT. Common in lifters over 35. TRT runs the anabolic baseline; MOTS-c layers in for metabolic flexibility and insulin sensitivity. No mechanistic conflict.

MOTS-c with a GH-axis stack. Pairs naturally with CJC-1295 plus ipamorelin or tesamorelin. GH-axis handles body composition and recovery signaling; MOTS-c handles the cellular metabolic side.

MOTS-c with GLP-1s. Less common and worth more caution. Both lower glucose; the combination could push insulin sensitivity further than expected. If you stack, start at the low end of MOTS-c dosing and monitor glucose closely.

MOTS-c with metformin or berberine. Same logic as the GLP-1 case. Plausible synergy, real hypoglycemia risk in lean users with good baseline insulin sensitivity. Track glucose.

What MOTS-c doesn't pair with: an absent baseline. The compound's effects are subtle enough that running it without tracking anything is almost guaranteed to produce a "didn't notice much" report regardless of whether it actually worked.

Common mistakes

Five patterns that show up in "MOTS-c didn't work for me" reports.

No baseline. Biggest reason by a wide margin. The felt response is subtle. Without two weeks of pre-cycle data on energy, RHR, and glucose, there's nothing to compare against.

Bad sourcing. Second biggest. Mislabeled or underdosed gray-market product is the standard hidden variable in any "it didn't work" report on a research-only peptide.

Expecting GLP-1-level effects. MOTS-c isn't a weight loss drug. It's a metabolic signaler. Body composition changes (when they happen) are modest and gradual.

Stopping after two weeks. The felt response, when present, builds across 3 to 6 weeks. Two weeks is below the floor for most users.

Running it without a metabolic problem to address. A 25-year-old with great baseline insulin sensitivity and a clean lipid panel is unlikely to feel much. MOTS-c does more in users with room to move metabolically.

Where MOTS-c fits in the broader picture

If you're trying to figure out where MOTS-c belongs in your stack, the practical sequence most metabolically-focused users land on is: address sleep, training, and nutrition first; layer in TRT if hypogonadal; consider a GH-axis peptide like CJC-1295 plus ipamorelin for body composition support; consider MOTS-c if metabolic flexibility, glucose handling, or exercise capacity is the specific job left to do. It's a niche addition, not a foundation.

For the broader body composition picture, see the Body Recomposition with Peptides pillar. For the fat-loss angle specifically, see Best Peptides for Fat Loss 2026.

Frequently asked questions

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome that signals to skeletal muscle, the liver, and adipose tissue to improve glucose handling, fat oxidation, and metabolic flexibility. It's part of a broader family of mitochondrial-derived peptides that includes humanin and the SHLPs. Endogenous MOTS-c levels decline with age and rise transiently with exercise.

Is MOTS-c an "exercise mimetic"?

The framing comes from mouse studies showing that exogenous MOTS-c activates AMPK and improves endurance in ways that overlap with exercise adaptation. In humans, the data is much thinner. The honest version is that MOTS-c shares mechanisms with exercise but is not a substitute for it.

What's the typical MOTS-c dose?

The most common community protocol is 5 to 10 mg subcutaneously two to three times per week. A smaller subset runs 1 to 2 mg daily. There is no FDA-approved dosing for human use, and no human efficacy trials at these doses. Most users start at the low end and titrate.

How long until MOTS-c works?

Most community reports describe noticeable changes (energy, RHR, exercise capacity) within 3 to 6 weeks. Body composition and lab marker changes, when they happen, typically take 8 to 12 weeks. If you're at 6 weeks with no change, common reasons are wrong dose, sourcing problems, or no metabolic room to move in your baseline.

Is MOTS-c FDA-approved?

No. MOTS-c is not FDA-approved for any indication. It sits on the FDA's Category 2 list and is on the agenda for the FDA's Pharmacy Compounding Advisory Committee meeting on July 23 to 24, 2026, alongside BPC-157, TB-500, KPV, DSIP, Semax, and Epitalon.

Is MOTS-c banned by WADA?

MOTS-c is not a named substance on the WADA prohibited list, but the broader S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) is interpreted broadly. The safe assumption for any tested athlete is that any peptide outside an approved medication carries meaningful risk. Do not run MOTS-c in tested sport without explicit guidance from your anti-doping authority.

Can MOTS-c cause low blood sugar?

In healthy users running MOTS-c alone, symptomatic hypoglycemia is rare in community reports. The real risk is in combination: stacking MOTS-c with insulin, sulfonylureas, GLP-1s at full dose, or aggressive carbohydrate restriction can push glucose too low, especially in lean users with already-good baseline insulin sensitivity. Monitor glucose if you're stacking.

Can I stack MOTS-c with TRT?

Yes, and it's the most common stack pattern in community protocols. TRT runs the anabolic baseline; MOTS-c layers in for metabolic flexibility and insulin sensitivity. There's no known mechanistic conflict between the two.

How do I track MOTS-c effects?

Energy, exercise capacity, and resting heart rate are the felt-response markers. Body composition (weight, body fat percentage) and fasting glucose, HbA1c, and lipid panel are the objective markers worth pulling on a cycle. Start logging two weeks before the protocol so you have a baseline. Regimen's MOTS-c tracker handles all of these with dose-overlay visualization.

Track MOTS-c against energy, RHR, and metabolic markers.

Multi-compound stack support (TRT, GH-axis, GLP-1)
Apple Health and Health Connect sync (RHR, sleep, glucose)
Cycle on/off scheduling with side-effect notes

MOTS-c Guide: Mitochondrial Peptide, Evidence, Protocols